Xeris Biopharma Holdings
XERS
103 hedge funds and large institutions have $147M invested in Xeris Biopharma Holdings in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 28 increasing their positions, 28 reducing their positions, and 10 closing their positions.
909% more call options, than puts
Call options by funds: $2.49M | Put options by funds: $247K
110% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 10
82% more capital invested
Capital invested by funds: $80.4M → $147M (+$66.1M)
12% more funds holding
Funds holding: 92 → 103 (+11)
4.7% more ownership
Funds ownership: 36.03% → 40.73% (+4.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$10.1M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.23M |
| 3 |
Millennium Management
New York
|
+$4.61M |
| 4 |
BlackRock
New York
|
+$2.35M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$7.99M |
| 2 |
JP Morgan Chase
New York
|
-$1.18M |
| 3 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$1.01M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$720K |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$695K |
XERS Hedge Fund Activity: Q2 2023 in Review
103 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2023, worth a combined $147M — up 82% from $80.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new XERS positions and 10 closed out — a net gain of 11 holders — while 28 added to existing stakes and 28 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $10.1M. The largest seller was Stonepine Capital Management, cutting an estimated $7.99M.
- 103 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2023, up from 92 in Q1 2023.
- Funds reported $147M of Xeris Biopharma Holdings stock for Q2 2023, up 82% quarter-over-quarter.
- 21 funds opened new Xeris Biopharma Holdings positions in Q2 2023 and 10 closed out, a net change of +11 holders.
- The largest Xeris Biopharma Holdings buyer in Q2 2023 was MPM BioImpact, an estimated $10.1M added.
- The largest Xeris Biopharma Holdings seller in Q2 2023 was Stonepine Capital Management, an estimated $7.99M sold.
Based on aggregated 13F filings for Q2 2023.